Gilead's revenue is anchored by Biktarvy, protected by exclusivity through 2036, reducing near-term patent cliff risk vs. peers. Learn more about GILD stock here.
Interim financial results, Q1 2025/261 October 2025 - 31 December 2025 Coloplast delivered Q1 organic growth of 6% and EBIT growth1 in constant currencies of 3%. Reported revenue in DKK grew 0%, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results